Gottlieb Advances, But FDA's Future Seems Increasingly Partisan
Senate committee votes to send the FDA Commissioner nominee to the Senate floor, but with only two Democratic votes.
You may also be interested in...
US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.
Gottlieb favors making the letters detailing application problems public, but industry still may oppose it; Senate schedules cloture vote for confirmation.
Given that 'right to try' is intended to be a patient-centered proposal, patient organizations are a strong voice in opposition, working behind the scenes to revise – or entirely exclude – the legislation as part of the user fee package. But the bill also has powerful advocates among Senate Republicans and in the Trump Administration.